 |
| February
10, 2026 |
| Covering
Life Sciences Drugs, Diagnostics, Devices,
Digital Health |
|
|
|
* may need subscription to view |
 |
 |
| Boston's
most flexible contract vivarium
lab space: Start with a few study
cages and grow. |
|
Learn More
→ |
|
|
- Azenta Life Sciences and Frontier Space:
Strategic Partnership to Advance Space-Based
Life Sciences Research Infrastructure
More
- Biofrontera: Positive Results in Phase 3
Study of Ameluz PDT for Actinic Keratoses on
the Extremities, Neck, and Trunk, Meeting
Primary Endpoint More
- Butterfly Network: Achieves GovRAMP and
TX-RAMP Information Security Certifications More
- Dana-Farber: Research Helps Drive FDA Label
Update for Primary CNS Lymphoma More
- Helus Pharma: Appoints Michael Cola as
Chief Executive Officer to Lead Next Phase
of Scale and Execution More
- Kailera Therapeutics and Hengrui Pharma:
Positive Topline Data From Phase 2 Obesity
Trial of Oral Ribupatide More
More*
- Moderna: Will Enter into Long-Term Strategic
Agreement With the Government of Mexico More
- NeuroSense: Expands Global IP Protection
Strategy With Granted Australian Patent
Covering PrimeC Composition More
- Oryzon Genomics: First Patient Dosed in an
Investigator-Initiated Phase Ib Study of
Iadademstat in Extensive Stage Small Cell Lung
Cancer More
- PharmaEssentia: Plans to Establish New U.S.
Manufacturing Facility in Puerto Rico to
Support Global Growth of BESREMi More
- ProQR: Planned Changes to Board Composition
More
- SCIEXL Echo MS+ System Integration With
ZenoTOF 8600 System, Delivering Enhanced
Sensitivity for High-Throughput Screening More
- Solid Biosciences: Positive Feedback From
Type C Meeting With FDA for SGT-003 Gene
Therapy for Duchenne Muscular Dystrophy
More
- Takeda: U.S. Food and Drug Administration
Accepts New Drug Application and Grants
Priority Review for Oveporexton (TAK-861) as a
Potential First-in-Class Therapy for
Narcolepsy Type 1 More
- TransMedics: Receives Full and Unconditional
FDA IDE Approval for Next-Generation OCS Heart
ENHANCE Trial More
- ZOLL:
New ZOLL Zenix Monitor/Defibrillator Receives
MDR Approval More
|
|
 |
Charles
River CFO
From JPM 2026 insights to
execution,
CRCFO delivers the right-sized
financial expertise
your company needs now. |
|
Learn More
→ |
|
|
|
- C4 Therapeutics: Inducement Grant Under
Nasdaq Listing Rule 5635(c)(4)
More
- Enanta Pharmaceuticals: Financial Results
for its Fiscal First Quarter Ended December
31, 2025 More
- Generation Bio Pays Landlord $21.5M to
Escape Lease Early After Xoma Buyout More*
- Get Full Access to BYTE51 Life Sciences
Intelligence for 50% Off More
- Harvard Bioscience: Preliminary Fourth
Quarter Financial Results, Positive Outlook
for 2026 & Outlines Long-Term Strategic
Focus Areas More
- Kainova Therapeutics: Secures $32M CAD to
Accelerate Development of Immuno-Oncology and
Inflammation Therapies More
- More on Eli Lilly Acquiring ‘World’s Most
Innovative Biotech Startup’ for Up to $2.4B
More*
More*
More*
More
- Thermo Fisher Scientific: Prices Offering of
USD-Denominated Senior Notes More
- Waters: Completes Combination With BD's
Biosciences & Diagnostic Solutions
Businesses More
- Waters: Fourth Quarter and Full-Year 2025
Financial Results More
|
|
|
 |
Pace®
Life Sciences
The CDMO That Takes You Further.
Your partner for Product
Development, Manufacturing,
Analytical Testing, Regulatory
Consulting & Operational
Support. |
|
Learn More
→ |
|
|
|
- Broad Institute: Clinical Trial Explores
Whether a Genetic Test Can Improve Early
Detection of Prostate Cancer More
- Hold Onto That Cup o’ Joe: Study Finds
Moderate Caffeine Intake May Reduce Dementia
Risk
More
- More on SC Leqembi Landing Priority Review
in China More*
- Subscribe to LifeSci Startup for
Updates on US Startups More
- The Big4Bio Podcast: Every Moment
Matters: The Power of Study Director–Advisor
Partnerships Podcast
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: Boston Life Science
Company Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
Feature your company |
| Apply
to have your company
showcased by Big4Bio |
|
|
|
|
|
 |
| Life
Sciences Talent and Consulting
Strategist George Quinn Named
Partner, Fractional Talent at
Slone Partners |
|
Learn More
→ |
|
|
- AI in Biotech: The New Frontier for
Leadership & Strategy More
- Employers Warm Up to Remote Workers Again:
BioSpace Report More
- From Seed to Series C: What
Investors Look for Beyond the Science More
- ICYMI: CEO’s Perspective: Big Moves Come
with Big Responsibility More
- ICYMI: CEO’s Perspective: The High Cost of
Job Hopping More
- ICYMI: Elevating Executive Presence: A
Blueprint for Life Sciences and Biotech
Leaders More
- M&A in Life Sciences: The Turning Tide –
Why Now is a Strategic Inflection for
Biopharma and Biotech More
- Partnership Targets First-Generation
Students for Bioscience Careers More*
- The Rise of Fractional Talent in Life
Sciences: What to Expect in 2026 More
|
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:Boston,
all rights reserved 2026
© 2026
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
